Intellectual Property

Clinical Genomics' intellectual property includes up-regulated and down-regulated biomarkers for colorectal neoplasia. Our extensive biomarker portfolio forms the core IP being exploited in Clinical Genomics' diagnostic product development program. In addition to its proprietary biomarker panel, Clinical Genomics is actively developing biomolecule and cellular separation technologies to assist in the enrichment of rare cells and biomarker transcripts.  These innovations are the subject of patents-pending that Clinical Genomics believes have broad application in improving the sensitivity of molecular diagnostic tests across the disease spectrum.